Neurocrine Biosciences, Inc. (NB3.F)
| Previous close | 130.45 |
| Open | 130.00 |
| Bid | 130.55 x 50000 |
| Ask | 0.00 x 50000 |
| Day's range | 130.00 - 135.75 |
| 52-week range | 83.18 - 135.75 |
| Volume | |
| Avg. volume | 17 |
| Market cap | 13.661B |
| Beta (5Y monthly) | 0.28 |
| PE ratio (TTM) | 39.69 |
| EPS (TTM) | 3.42 |
| Earnings date | 30 Jul 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 122.19 |
PR NewswireNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1117567 in healthy adult participants. NBI-1117567 is an investigational, oral, M1/M4 (M1 preferring) selective muscarinic agonist for the potential treatment of neurological and neuropsychiatric conditions.
- PR Newswire
Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the BofA Securities 2024 Health Care Conference at 11:20 a.m. Pacific Time (2:20 p.m. Eastern Time) on Tuesday May 14, 2024 in Las Vegas. Kevin Gorman, Chief Executive Officer, Matt Abernethy, Chief Financial Officer, and Kyle Gano, Chief Business Development and Strategy Officer, will present at the conference.
- PR Newswire
Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present key information from its neuroendocrinology pipeline, including baseline characteristics data from its CAHtalyst™ Program of crinecerfont in congenital adrenal hyperplasia (CAH), as well as data from its modified-release hydrocortisone studies in primary adrenal insufficiency and CAH, at the European Congress of Endocrinology 2024 meeting in Sweden, May 11–14.
